SLS
SELLAS Life Sciences Group, Inc.
Key Financials
Operating Income
$-28274000
↑ 10.3%
Revenue
$0
↓ 100.0%
Net Income
$-26863000
↑ 13.0%
Gross Profit
$967000
↓ 61.9%
EPS (Diluted)
$-0.25
↑ 50.0%
Shareholders' Equity
$70.9M
↑ 648.8%
Total Assets
$78.3M
↑ 303.2%
Total Liabilities
$7.5M
↓ 25.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 3/27/2026 | View on SEC |
| S-3ASR | 3/20/2026 | View on SEC |
| 8-K | 3/19/2026 | View on SEC |
| 10-K | 3/19/2026 | View on SEC |
| 8-K | 3/11/2026 | View on SEC |
| SCHEDULE 13G/A | 2/17/2026 | View on SEC |
| SCHEDULE 13G/A | 1/30/2026 | View on SEC |
| 4 | 1/9/2026 | View on SEC |
| 4 | 1/9/2026 | View on SEC |
| 4 | 1/9/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | SLS |
| Company Name | SELLAS Life Sciences Group, Inc. |
| CIK | 1390478 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 6462005278 |